Clinical trial
Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
NCT04919252 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
- Lead sponsor
- Yonsei University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- June 1, 2021
- Completion date
- January 31, 2023
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
crohn's disease and ulcerative colitis